Lucence Health develops liquid biopsy technologies, including the AmpliMark™ test, which detects cancer biomarkers with over 99% sensitivity at a 0.1% mutant allele frequency. Their LiquidHALLMARK® test enables earlier cancer detection through a single blood draw, providing actionable insights for targeted treatment.
Funding
$29.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IHFounders
Product
Problem
Detecting cancer early and monitoring its progression often requires invasive tissue biopsies, which can be risky, painful, and may not always capture the full heterogeneity of the tumor. Traditional methods may also lack the sensitivity needed to detect early-stage cancers or minimal residual disease.
Solution
Lucence Health offers non-invasive liquid biopsy tests for early cancer detection and treatment monitoring, utilizing both circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) analysis. Their proprietary AmpliMark™ technology enables highly sensitive detection of cancer biomarkers from a single blood draw, achieving >99% sensitivity at a 0.1% mutant allele frequency. The LiquidHALLMARK® test, powered by AmpliMark™, provides physicians with actionable insights to guide personalized cancer care, allowing for earlier intervention and more effective treatment strategies. By capturing both sequence and cell information, Lucence aims to improve diagnostic yield and provide a comprehensive profile of the tumor.
Target Audience
The primary target audience includes oncologists, pathologists, and other healthcare providers involved in cancer diagnosis, treatment, and monitoring, as well as patients seeking non-invasive options for early cancer detection and personalized treatment strategies.
Features
- LiquidHALLMARK® test combining ctDNA and ctRNA analysis for improved diagnostic yield
- AmpliMark™ technology for highly sensitive biomarker detection (>99% sensitivity at 0.1% MAF)
- Non-invasive blood test, eliminating the need for tissue biopsies
- Detection of clinically relevant biomarkers for lung, breast, and blood cancers
- Monitoring of treatment response and detection of minimal residual disease
- Actionable insights for personalized cancer care
- Medicare coverage for LiquidHALLMARK®